Cargando…

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study

PURPOSE: Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. MicroRNAs (miRNAs) have been suggested as promising biomarkers and we here evaluated whether a miRNA profile could be identified, sub-grouping ER+ breast cancer pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyng, Maria B., Lænkholm, Anne-Vibeke, Søkilde, Rolf, Gravgaard, Karina H., Litman, Thomas, Ditzel, Henrik J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356496/ https://www.ncbi.nlm.nih.gov/pubmed/22623953 http://dx.doi.org/10.1371/journal.pone.0036170

Ejemplares similares

Gene Expression Signatures That Predict Outcome of Tamoxifen-Treated Estrogen Receptor-Positive, High-Risk, Primary Breast Cancer Patients: A DBCG Study
por: Lyng, Maria B., et al.
Publicado: (2013)

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer
por: Gravgaard, KH, et al.
Publicado: (2011)

Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study
por: Kodahl, Annette R., et al.
Publicado: (2014)

Identification of genes for normalization of real-time RT-PCR data in breast carcinomas
por: Lyng, Maria B, et al.
Publicado: (2008)

miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations
por: Thomsen, Karina G., et al.
Publicado: (2015)

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
por: Skriver, Signe Korsgaard, et al.
Publicado: (2020)

Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial
por: Shenasa, Elahe, et al.
Publicado: (2022)

Intratumor Genetic Heterogeneity of Breast Carcinomas as Determined by Fine Needle Aspiration and TaqMan Low Density Array
por: Lyng, Maria B., et al.
Publicado: (2007)

Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)
por: Cold, S, et al.
Publicado: (2005)

MicroRNA Expression Profiling of the Porcine Developing Brain
por: Podolska, Agnieszka, et al.
Publicado: (2011)

Selection criteria for early breast cancer patients in the DBCG proton trial – The randomised phase III trial strategy
por: Stick, Line Bjerregaard, et al.
Publicado: (2021)

Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy
por: Elias, D., et al.
Publicado: (2019)

Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer
por: Joshi, Tejal, et al.
Publicado: (2016)

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
por: Prat, A., et al.
Publicado: (2012)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment
por: Larsen, Sarah L., et al.
Publicado: (2015)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
por: Frogne, Thomas, et al.
Publicado: (2009)

Progestins and the endometrium in patients receiving tamoxifen
Publicado: (1999)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer
por: Larsen, Sarah L, et al.
Publicado: (2015)

Adjuvant vitamin C for sepsis: mono or triple?
por: Spoelstra–de Man, Angelique M. E., et al.
Publicado: (2019)

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
por: Huang, Yu-Hsiang, et al.
Publicado: (2018)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer
por: Kodahl, Annette R., et al.
Publicado: (2018)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials
por: Kyndi, Marianne, et al.
Publicado: (2008)

Syringomatous Tumour Presenting as Inversion of a Supernumerary Nipple
por: Öwall, Louise, et al.
Publicado: (2019)

Bone mineral content of women receiving tamoxifen for mastalgia.
por: Fentiman, I. S., et al.
Publicado: (1989)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Tamoxifen-independent Cre-activity in SMMHC-CreER(T2) mice
por: Steffensen, L.B., et al.
Publicado: (2022)

The Christie hospital adjuvant tamoxifen trial--status at 10 years.
por: Ribeiro, G., et al.
Publicado: (1988)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
por: Uslu, Yasemin, et al.
Publicado: (2023)

Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial
por: Thomsen, M.S., et al.
Publicado: (2021)

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5o32dd2fkcomrmtdee5ges3uk1